Clinical trials: Advanced Carcinoma
Non-small Cell Lung Cancer
Real World Study on First Line Crizotinib in ROS1 Rearranged Advanced Non-squamous Non-small Cell Lung Cancer
This study was designed to explore the efficacy and safety of Crizotinib as a first-line treatment for advanced NSCLC with ROS1 rearrangement positive mutation in the real world, explore the new drug resistance mechanism of ROS1…
- Trial name
- NCT03646994
- Testing
- Crizotinib
- Where
- China
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Hunan Province Tumor Hospital
Non Small Cell Lung Cancer
The APRIL Trial Evaluating Upfront Stereotactic Body Radiotherapy in Stage III Advanced Non-small Cell Lung Cancer
The aim of the study is to test the feasibility \& loco-regional control rate by combining high precision SBRT with chemotherapy in stage III NSCLC in tumor/lymph nodes if tumors/lymph node size with ≤ 6cms in size.
- Trial name
- APRIL (NCT07565987)
- Testing
- SBRT in stage III NSCLC
- Where
- India
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- All India Institute of Medical Sciences
Carcinoma, Hepatocellular
A Study of Electromagnetic Waves in the Treatment of the Advanced Hepatocarcinoma
Hepatocarcinoma (HCC) is the first cause of deaths due to cancer worldwide. More than one million two hundred thousand new patients are diagnosed each year.
- Trial name
- THBC002 (NCT00440934)
- Testing
- Amplitude-modulated electromagnetic fields
- Where
- Switzerland
- Volunteers
- healthy volunteers welcome
- Sponsor
- Pasche, Boris, M.D.
Advanced Hepatocellular Carcinoma
Concurrent Nivolumab and External Beam Radiation Therapy for Patients With Advanced HCC
To investigate the efficacy and safety of nivolumab for patients with advanced HCC undergoing EBRT
- Trial name
- Nextrah (NCT04611165)
- Testing
- Nivolumab
- Where
- South Korea
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- National Cancer Center, Korea
Advanced Renal Cell Carcinoma
Efficacy and Safety of Fruquintinib in Combination With Sintilimab in Advanced Renal Cell Carcinoma (FRUSICA-2)
The study consists of two parts, the first part is a randomized, open-label, active-controlled study to evaluate the efficacy and safety of fruquintinib in combination with sintilimab versus axitinib or everolimus monotherapy as…
- Trial name
- NCT05522231
- Testing
- fruquintinib+sintilimab, axitinib / everolimus, fruquintinib
- Where
- 48 sites in China
- Volunteers
- 265 people, healthy volunteers welcome
- Sponsor
- Hutchmed
Stage IV Melanoma, Advanced Lung Cancer
Improving Patient and Caregiver Understanding of Risks and Benefits of Immunotherapy for Advanced Cancer
The purpose of this study is to refine and pilot test educational material developed to educate and support patients receiving immunotherapy for advanced cancer.
- Conditions
- Stage IV Melanoma, Advanced Lung Cancer, Stage IV Non-Small Cell Lung Cancer, Unresectable Non-Small Cell Lung Carcinoma
- Trial name
- UPLIFT (NCT04670445)
- Testing
- Educational Video and QPL List, Usual Care
- Where
- United States
- Volunteers
- 199 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
Advanced Squamous Cell Carcinoma, Squamous Cell Carcinoma of Head and Neck
Study of Docetaxel in Combination With Cisplatin and 5-Fluorouracil in Locally Advanced Squamous Cell Carcinoma of the Head and Neck
The purpose of this study is to determine the appropriate dose, that dose which is found to give maximum effect with limited toxicity, of cisplatin in combination with docetaxel and 5-fluorouracil and then to further define the…
- Conditions
- Advanced Squamous Cell Carcinoma, Squamous Cell Carcinoma of Head and Neck, SSCHN
- Trial name
- NCT00139269
- Testing
- Docetaxel, Cisplatin, 5-Fluorouracil
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- Dana-Farber Cancer Institute
Non-small Cell Lung Cancer
FMT+Immunotherapy+Chemotherapy As First-line Treatment for Driver-gene Negative Advanced NSCLC
This study plans to reconstruct intestinal microecology through fecal microbiota transplantation (FMT), and combine with standard first-line therapy to enhance the anti-tumor immune effect at the same time, thereby extending the…
- Trial name
- NCT06403111
- Testing
- Fecal Microbiota Transplantation (FMT)+chemotherapy+immunotherapy
- Where
- China
- Volunteers
- 62 people, healthy volunteers welcome
- Sponsor
- Changzhou No.2 People's Hospital
Hepatocellular Carcinoma
Safety and Efficacy of Allogeneic NK Cells Therapy in Patients With Advanced Hepatocellular Carcinoma
This is a multicenter, open-label, paired control study to evaluate the safety and clinical efficacy of allogeneic NK cells combined with targeted drug in the treatment for advanced HCC.
- Trial name
- NCT04162158
- Testing
- allogeneic NK cells therapy
- Where
- China
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Beijing 302 Hospital
Squamous Cell Carcinoma of Head and Neck
Concurent Chemoradiotherapy in Head and Neck Cancers
To compare the efficacy and toxicities of the combination between weekly docitaxel and cisplatin (every3 week) concurrent with radiation versus the standard concurrent chemoradiotherapy with high dose cisplatin (100mg\m2) for…
- Trial name
- NCT04780750
- Testing
- Docetaxel
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Assiut University
Non Small Cell Lung Cancer
Taletrectinib Phase 2 Global Study in ROS1 Positive NSCLC
The main purpose of the study is to evaluate safety and efficacy of taletrectinib (also known as AB-106 or DS-6051b) monotherapy in the treatment of advanced NSCLC.
- Trial name
- TRUST-II (NCT04919811)
- Testing
- Taletrectinib
- Where
- 77 sites in United States, Canada and 7 more
- Volunteers
- 217 people, healthy volunteers welcome
- Sponsor
- Nuvation Bio Inc.
Metastatic Biliary Tract Carcinoma
A Phase 2 Trial of Regorafenib as A Single Agent in Advanced and Metastatic Biliary Tract Carcinoma/Cholangiocarcinoma Patients Who Have Failed First-line Chemotherapy
Based on the facts of multiple pathways involvement in cholangiocarcinoma tumor genesis, including EGFR, Ras, Raf, VEGFR, and PDGFR, with evidence of overexpression of these proteins associated with tumor stage, prognosis and…
- Trial name
- NCT02053376
- Testing
- Regorafenib
- Where
- United States
- Volunteers
- 43 people, healthy volunteers welcome
- Sponsor
- Nathan Bahary, MD
Non-small Cell Lung Cancer
ALK Tyrosine Kinase Inhibitors in ALK-rearranged Advanced Squamous Cell Carcinoma
This study was to explore the efficacy of ALK-TKI in lung squamous cell carcinoma. Approximately 5% of lung adenocarcinomas have oncogenic fusions of EML-4 and ALK a mutation associated with tumorigenesis and migration.
- Trial name
- ATPase (NCT05014464)
- Testing
- Crizotinib
- Where
- China
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Hunan Province Tumor Hospital
Acute Myelogenous Leukemia, Ovarian Cancer
Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers
To evaluate the safety, tolerability, and anti-tumor activity of galinpepimut-S in combination with pembrolizumab in patients with selected advanced cancers.
- Conditions
- Acute Myelogenous Leukemia, Ovarian Cancer, Colorectal Cancer, Triple-negative Breast Cancer
- Trial name
- NCT03761914
- Testing
- galinpepimut-S, pembrolizumab, Montanide
- Where
- 12 sites in United States
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Sellas Life Sciences Group
Head and Neck Squamous Cell Carcinoma
An Experimental Study to Compare Treatment Response and Toxicities of Concurrent Chemoradiation With Weekly Cisplatin and Three Weekly Cisplatin in Locally Advanced Head and Neck Cancer.
The aim of this study is to compare treatment responses and toxicities of concurrent chemo-radiation with weekly and three weekly Cisplatin in locally advanced Head \& Neck Cancer.
- Trial name
- HNC (NCT03998696)
- Testing
- Cisplatin 40 mg/m2, Cisplatin 100 mg/m2
- Where
- Bangladesh
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
Oropharyngeal Carcinoma
Anti-EGFR Therapy With IMRT Concurrent Chemoradiotherapy in Locally Advanced OPC Resistant to Induction Chemotherapy
This study is a prospective phase II trial which is designed to evaluate the efficacy and safety of IMRT combined with concurrent chemotherapy and anti-EGFR monoclonal antibody in locally advanced oropharyngeal carcinoma (OPC)…
- Trial name
- NCT04508829
- Testing
- Anti-EGFR monoclonal antibody
- Where
- China
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Fudan University
Renal Cell Carcinoma
MRI in Renal Tumors
Diagnostic imaging for renal masses of unknown nature using conventional imaging modalities such as 3 phase contrast-enhanced computed tomography (CT) is not always conclusive.
- Trial name
- NCT02325921
- Testing
- Magnetic Resonance Imaging
- Where
- Netherlands
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- Radboud University Medical Center
Colorectal Cancer, Colorectal Neoplasms
Early Detection of Advanced Adenomas and Colorectal Cancer
This study aims to develop a highly sensitive, specific, and cost-effective blood assay for early detection of colorectal adenomas and cancer, using advanced machine learning and state-of-the-art biological analyses.
- Conditions
- Colorectal Cancer, Colorectal Neoplasms, Colorectal Polyp, Colorectal Adenocarcinoma
- Trial name
- AACRC (NCT06342440)
- Testing
- DENEB
- Where
- 6 sites in United States, China and 3 more
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- City of Hope Medical Center
Non-Small Cell Lung Cancer
Evaluation of PD1 / PDL1 Expression on Blood Cells & Tumor Tissue, Their Role as a Prognostic Target in NSCLC Patients
Several reports have examined Programmed Death 1 (PD-1) expression on tumor-infiltrating T-cells, and its correlation with prognosis has been discussed.
- Trial name
- NCT02758314
- Testing
- Evaluation of PD-1/PDL-1 expression.
- Where
- Mexico
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Instituto Nacional de Cancerologia de Mexico
Metastatic Melanoma, Metastatic Breast Cancer
Quantifying Systemic Immunosuppression to Personalize Cancer Therapy
It is nowadays well established that the immune system can profoundly influence disease outcome in cancer patients. Increasing evidence is indeed showing that patients displaying spontaneous T cell-mediated immune response…
- Conditions
- Metastatic Melanoma, Metastatic Breast Cancer, Advanced Renal Cell Carcinoma, Squamous Cell Carcinoma of Head and Neck
- Trial name
- SERPENTINE (NCT04941365)
- Testing
- single arm
- Volunteers
- healthy volunteers welcome
- Sponsor
- Institut du Cancer de Montpellier - Val d'Aurelle